Biotech Values

[RockRat]

>>In this instance, the arithmetic is moot, IMO.<<

If Momenta succeeds with generic Copaxone the lost generic enoxaparin profits would loom much larger.

>> I see zero chance of a shareholder suit against Teva succeeding on the basis of dishonest comments about generic Lovenox by Teva’s executives.<<

Especially if Teva does not have to contend with generic Copxaone, you could be right. I assume the basis of your assessment is founded on the concept that Teva and its stock price will perform well enough that investors will have a hard time demonstrating harm. If not, what is the basis of your zero chance assessment?

Regards, RockRat